This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.The BARI 2D trial is an NIH-sponsored, investigator-initiated, multicenter clinical trial whose objective is to determine, in patients with Type 2 diabetes mellitus and stable, documented coronary artery disease, whether 5-year mortality is lower with (1) a strategy of initial coronary revascularization (either PTCA or CABG) combined with intensive medical therapy vs intensive medical therapy alone, and (2) glycemic control achieved by an insulin sensitizaton regimen vs an insulin provision regimen (both to a target HbA1c level of <7.0%). UAB is one of about 50 clinical centers participating in this trial of about 2400 patients with follow-up of 5-7 years.
Showing the most recent 10 out of 570 publications